Viracta Therapeutics to Host R&D Day on October 4, 2023
05 September 2023 - 3:00PM
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage
precision oncology company focused on the treatment and prevention
of virus-associated cancers that impact patients worldwide, today
announced that it will host a Research and Development (R&D)
Day on Wednesday, October 4, 2023, focused on Nana-val, its
all-oral investigational therapy targeting Epstein-Barr virus
(EBV)-associated cancers.
The R&D Day is scheduled for October 4,
2023, from 8:00 a.m. to 10:00 a.m. EDT, and will include formal
presentations followed by a Q&A session. Members of Viracta’s
senior management team will provide updates on Nana-val’s
development programs, and the following Key Opinion Leaders are
scheduled to present on Nana-val’s opportunity to address the unmet
medical needs of this unique cancer segment:
- Pierluigi Porcu, M.D., Professor of
Medical Oncology, Director of the Division of Hematologic
Malignancies and Hematopoietic Stem Cell Transplantation,
Department of Medical Oncology at Thomas Jefferson University
- Robert A. Baiocchi, M.D., Ph.D.,
Professor of Internal Medicine, Associate Director for
Translational and Clinical Science in the Division of Hematology at
The Ohio State University
A live video webcast of the presentation will be
available on the Investors section of the Viracta website under
"Events and Webcasts" and archived for at least 30 days following
the event.
About Viracta Therapeutics,
Inc.Viracta is a clinical-stage precision oncology company
focused on the treatment and prevention of virus-associated cancers
that impact patients worldwide. Viracta’s lead product candidate is
an all-oral combination therapy of its proprietary investigational
drug, nanatinostat, and the antiviral agent valganciclovir
(collectively referred to as Nana-val). Nana-val is currently being
evaluated in multiple ongoing clinical trials, including a pivotal,
global, multicenter, open-label Phase 2 basket trial for the
treatment of multiple subtypes of relapsed or refractory
Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a
multinational, open-label Phase 1b/2 trial for the treatment of
patients with recurrent or metastatic EBV+ nasopharyngeal carcinoma
and other advanced EBV+ solid tumors. Viracta is also pursuing the
application of its “Kick and Kill” approach in other virus-related
cancers.
For additional information please visit
www.viracta.com.
Investor Relations Contact:Ashleigh BarretoHead
of Investor Relations & Corporate CommunicationsViracta
Therapeutics, Inc.abarreto@viracta.com
SOURCE Viracta Therapeutics, Inc.
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024